4.5 Article

Engineering Specificity from Broad to Narrow: Design of a β-Lactamase Inhibitory Protein (BLIP) Variant That Exclusively Binds and Detects KPC β-Lactamase

期刊

ACS INFECTIOUS DISEASES
卷 2, 期 12, 页码 81-91

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.6b00160

关键词

protein-protein interactions; protein engineering antibiotic resistance; beta-lactamase; enzyme inhibition; diagnostics

资金

  1. National Institutes of Health [AI092963, AI32956]

向作者/读者索取更多资源

The beta-lactamase inhibitory protein (BLIP) binds and inhibits a wide range of class A beta-lactamases including the TEM-1 beta-lactamase (K-i = 0.5 nM), which is widely present in Gram-negative bacteria, and the KPC-2 beta-lactamase (K-i = 1.2 nM), which hydrolyzes virtually all clinically useful beta-lactam antibiotics. The extent to which the specificity of a protein that binds a broad range of targets can be modified to display narrow specificity was explored in this study by engineering BLIP to bind selectively to KPC-2 beta-lactamase. A genetic screen for BLIP function in Escherichia coli was used to narrow the binding specificity of BLIP by identifying amino acid substitutions that retain affinity for KPC-2 while losing affinity for TEM-1 beta-lactamase. The combination of single substitutions yielded the K74T:W112D BLIP variant, which was shown by inhibition assays to retain high affinity for KPC-2 with a Ki of 0.4 nM, while drastically losing affinity for TEM-1 with a K-i > 10 mu M. The K74T:W112D mutant therefore binds KPC-2 beta-lactamase 3 times more tightly while binding TEM-1 > 20000-fold more weakly than wild-type BLIP. The K74T:W112D BLIP variant also exhibited low affinity (K, > 10 itM) for other class A fl-lactamases. The high affinity and narrow specificity of BLIP K74T:W112D for KPC-2 beta-lactamase suggest it could be a useful sensor for the presence of this enzyme in multidrug-resistant bacteria. This was demonstrated with an assay employing BLIP K74T:W112D conjugated to a bead to specifically pull-down and detect KPC-2 beta-lactamase in lysates from clinical bacterial isolates containing multiple beta-lactamases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Editorial Material Immunology

Birth Cohort Studies: Toward Understanding Protective Immunity to Human Noroviruses

Robert L. Atmar, Sasirekha Ramani

CLINICAL INFECTIOUS DISEASES (2021)

Article Virology

High-Resolution Mapping of Human Norovirus Antigens via Genomic Phage Display Library Selections and Deep Sequencing

Wanzhi Huang, Victoria Soeung, David M. Boragine, Liya Hu, B. V. Venkataram Prasad, Mary K. Estes, Robert L. Atmar, Timothy Palzkill

Summary: This study utilized a high-resolution method to map multiple antibody binding sites simultaneously from complex serum samples. The results indicated that a relatively small number of sites on the virus bind a large number of independently generated antibodies, suggesting that immunodominance plays a role in the humoral immune response to NoV infections.

JOURNAL OF VIROLOGY (2021)

Article Microbiology

New Insights and Enhanced Human Norovirus Cultivation in Human Intestinal Enteroids

Khalil Ettayebi, Victoria R. Tenge, Nicolas W. Cortes-Penfield, Sue E. Crawford, Frederick H. Neill, Xi-Lei Zeng, Xiaomin Yu, Vijayalakshmi Ayyar, Douglas Burrin, Sasirekha Ramani, Robert L. Atmar, Mary K. Estes

Summary: The study demonstrates that optimization of cultivation conditions in human intestinal enteroid cultures can effectively replicate multiple strains of human noroviruses (HuNoVs), which is crucial for research on HuNoV biology and the development of treatment methods.

MSPHERE (2021)

Letter Medicine, General & Internal

'String Test' for Hypermucoviscous Klebsiella pneumoniae

Elizabeth F. Eisenmenger, Emmanuel Guajardo, Natalie Finch, Robert L. Atmar, Zaven Sargsyan

AMERICAN JOURNAL OF MEDICINE (2021)

Article Immunology

Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults

Hana M. El Sahly, Robert L. Atmar, Eli Sendra, Ashley Wegel, Wendy A. Keitel

Summary: The study concluded that the combination of topical imiquimod with ID MIV A/H5N1 was safe but did not result in improved serologic responses to the vaccine.

JOURNAL OF INFECTIOUS DISEASES (2021)

Review Immunology

SARS-CoV-2 Vaccination During Pregnancy: A Complex Decision

Elizabeth Wenqian Wang, Jacqueline G. Parchem, Robert L. Atmar, Eva H. Clark

Summary: Despite the lack of data on vaccine safety in pregnant and breastfeeding individuals, the known risks of COVID-19 during pregnancy likely outweigh the potential risks of SARS-CoV-2 vaccines, which have demonstrated reassuring safety and efficacy profiles in nonpregnant populations.

OPEN FORUM INFECTIOUS DISEASES (2021)

Review Virology

Bile Goes Viral

Victoria R. Tenge, Kosuke Murakami, Wilhelm Salmen, Shih-Ching Lin, Sue E. Crawford, Frederick H. Neill, B. V. Venkataram Prasad, Robert L. Atmar, Mary K. Estes

Summary: Laboratory cultivation of viruses is essential for studying viral replication, detection methods, drug development, and antiviral research. Some viruses, such as human noroviruses and hepatitis B and C viruses, have difficulties replicating in cell lines, with tropism for the intestine and liver. Understanding the role of bile acids and receptors in virus replication is crucial for developing and optimizing culture systems for these viruses.

VIRUSES-BASEL (2021)

Article Primary Health Care

Case-based audit and feedback around a decision aid improved antibiotic choice and duration for uncomplicated cystitis in primary care clinics

Larissa Grigoryan, Roger Zoorob, George Germanos, Mohamad Sidani, Matthew Horsfield, Fareed Khan, Mohammad Zare, Melanie Goebel, Robert Atmar, Barbara Trautner

Summary: The multifaceted stewardship intervention significantly increased guideline adherence for antibiotic choice and duration in the treatment of uncomplicated cystitis, compared to the control group. Future research is needed to further explore the scalability and sustainability of similar interventions in primary care settings.

FAMILY MEDICINE AND COMMUNITY HEALTH (2021)

Article Medicine, General & Internal

Homologous and Heterologous Covid-19 Booster Vaccinations

R. L. Atmar, K. E. Lyke, M. E. Deming, L. A. Jackson, A. R. Branche, H. M. El Sahly, C. A. Rostad, J. M. Martin, C. Johnston, R. E. Rupp, M. J. Mulligan, R. C. Brady, R. W. Frenck, M. Backer, A. C. Kottkamp, T. M. Babu, K. Rajakumar, S. Edupuganti, D. Dobrzynski, R. N. Coler, C. M. Posavad, J. Archer, S. Crandon, S. U. Nayak, D. Szydlo, J. A. Zemanek, C. P. Dominguez Islas, E. R. Brown, M. S. Suthar, M. J. McElrath, A. B. McDermott, D. C. Montefiori, A. Eaton, K. M. Neuzil, D. S. Stephens, P. C. Roberts, J. H. Beigel

Summary: This study investigated the efficacy of homologous and heterologous booster vaccines in adults who had completed a primary Covid-19 vaccine regimen. The results showed that both types of booster vaccines were safe and immunogenic.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Letter Medicine, General & Internal

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Rolando Pajon, Nicole A. Doria-Rose, Xiaoying Shen, Stephen D. Schmidt, Sijy O'Dell, Charlene McDanal, Wenhong Feng, Jin Tong, Amanda Eaton, Maha Maglinao, Haili Tang, Kelly E. Manning, Venkata-Viswanadh Edara, Lilin Lai, Madison Ellis, Kathryn M. Moore, Katharine Floyd, Stephanie L. Foster, Christine M. Posavad, Robert L. Atmar, Kirsten E. Lyke, Tongqing Zhou, Lingshu Wang, Yi Zhang, Martin R. Gaudinski, Walker P. Black, Ingelise Gordon, Mercy Guech, Julie E. Ledgerwood, John N. Misasi, Alicia Widge, Nancy J. Sullivan, Paul C. Roberts, John H. Beigel, Bette Korber, Lindsey R. Baden, Hana El Sahly, Spyros Chalkias, Honghong Zhou, Jing Feng, Bethany Girard, Rituparna Das, Anne Aunins, Darin K. Edwards, Mehul S. Suthar, John R. Mascola, David C. Montefiori

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Review Virology

Glycan Recognition in Human Norovirus Infections

Victoria R. Tenge, Liya Hu, B. V. Venkataram Prasad, Goran Larson, Robert L. Atmar, Mary K. Estes, Sasirekha Ramani

Summary: Recognition of cell-surface glycans is crucial for virus attachment to host cells. Studies on HuNoVs show that HBGA glycan structures are important for infection, and the antibody-mediated neutralization mechanism has been explored. The use of novel culture systems has confirmed the necessity of fucosylated HBGAs for HuNoV infection.

VIRUSES-BASEL (2021)

Review Virology

Norovirus Protease Structure and Antivirals Development

Boyang Zhao, Liya Hu, Yongcheng Song, Ketki Patil, Sasirekha Ramani, Robert L. Atmar, Mary K. Estes, B. V. Venkataram Prasad

Summary: Human norovirus (HuNoV) infection is a global health and economic burden with no licensed vaccines or antiviral drugs available. Developing HuNoV protease inhibitors by targeting the enzyme's active site faces challenges due to subtle differential conformational flexibility and structural differences in the active site and substrate-binding pockets. Further comparative analysis of available HuNoV protease structures is needed to identify novel strategies for effective inhibitor design and development.

VIRUSES-BASEL (2021)

Article Critical Care Medicine

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial

Andre C. Kalil, Aneesh K. Mehta, Thomas F. Patterson, Nathaniel Erdmann, Carlos A. Gomez, Mamta K. Jain, Cameron R. Wolfe, Guillermo M. Ruiz-Palacios, Susan Kline, Justino Regalado Pineda, Anne F. Luetkemeyer, Michelle S. Harkins, Patrick E. H. Jackson, Nicole M. Iovine, Victor F. Tapson, Myoung-don Oh, Jennifer A. Whitaker, Richard A. Mularski, Catharine Paules, Dilek Ince, Jin Takasaki, Daniel A. Sweeney, Uriel Sandkovsky, David L. Wyles, Elizabeth Hohmann, Kevin A. Grimes, Robert Grossberg, Maryrose Laguio-Vila, Allison A. Lambert, Diego Lopez de Castilla, EuSuk Kim, LuAnn Larson, Claire R. Wan, Jessica J. Traenkner, Philip O. Ponce, Jan E. Patterson, Paul A. Goepfert, Theresa A. Sofarelli, Satish Mocherla, Emily R. Ko, Alfredo Ponce de Leon, Sarah B. Doernberg, Robert L. Atmar, Ryan C. Maves, Fernando Dangond, Jennifer Ferreira, Michelle Green, Mat Makowski, Tyler Bonnett, Tatiana Beresnev, Varduhi Ghazaryan, Walla Dempsey, Seema U. Nayak, Lori Dodd, Kay M. Tomashek, John H. Beigel

Summary: This study compared the efficacy of interferon beta-1a in combination with remdesivir versus remdesivir alone in hospitalised COVID-19 patients. The results showed no significant difference in time to recovery and mortality rate between the interferon beta-1a plus remdesivir group and the placebo plus remdesivir group, with patients requiring high-flow oxygen at baseline having poorer outcomes after interferon beta-1a treatment.

LANCET RESPIRATORY MEDICINE (2021)

Article Public, Environmental & Occupational Health

Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021

Gabriela Paz-Bailey, Laura Adams, Joshua M. Wong, Katherine A. Poehling, Wilbur H. Chen, Veronica McNally, Robert L. Atmar, Stephen H. Waterman

Summary: Dengue is a vectorborne infectious disease caused by closely related dengue viruses, transmitted mainly by Aedes mosquitoes. The Dengvaxia vaccine is recommended by ACIP for children aged 9-16 with previous dengue infection in endemic areas, as it is safe and effective in preventing severe dengue. Prior natural infection is important, as vaccination may increase the risk of severe dengue in individuals experiencing their first natural infection after vaccination.

MMWR RECOMMENDATIONS AND REPORTS (2021)

Article Public, Environmental & Occupational Health

Use of Ebola Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020

Mary J. Choi, Caitlin M. Cossaboom, Amy N. Whitesell, Jonathan W. Dyal, Allison Joyce, Rebecca L. Morgan, Doug Campos-Outcalt, Marissa Person, Elizabeth Ervin, Yon C. Yu, Pierre E. Rollin, Brian H. Harcourt, Robert L. Atmar, Beth P. Bell, Rita Helfand, Inger K. Damon, Sharon E. Frey

Summary: This report summarizes the recommendations for the use of the Ervebo Ebola vaccine in the United States, highlighting the contraindication for individuals with severe allergic reactions to rice protein. The vaccine is the first and only one licensed by the FDA for preventing EVD, with recommendations for preexposure vaccination for adults at highest risk.

MMWR RECOMMENDATIONS AND REPORTS (2021)

暂无数据